This multicenter observational study evaluates the impact of percutaneous edge-to-edge tricuspid valve repair on overall survival in patients with tricuspid regurgitation across different disease stages.
Meta-analysis of the longest available follow-up outcomes from the six main randomized trials comparing TAVI and SAVR in low surgical risk patients in terms of survival and stroke.
The Cardiac Surgery team at the Cleveland Clinic (Cleveland, Ohio, USA) reviewed multivalve reoperations (involving more than one valve) performed from 2008 to 2022 and identified the determinants of operative mortality in these procedures.
A retrospective observational study evaluating patients who underwent TAVI to identify predictive factors for atrioventricular block (AVB) within 24 hours to 30 days post procedure and to develop a risk stratification tool.
Dr. Juan Diego Sánchez’s perspective on the current state of the art in tricuspid regurgitation treatment.
This study provides increasingly necessary information to optimize decision-making in a population traditionally underrepresented in TAVI clinical trials: nonagenarian patients.
This retrospective study analyzes the outcomes and trends in the utilization of transatrial transcatheter mitral valve replacement (TA-TMVR) in high-risk patients with mitral annular calcification (MAC) between 2014 and 2021 in the U.S. population.
Comparative study on the behavior of TAVI prostheses implanted in bicuspid and tricuspid aortic valves, focusing on deformation, development of paravalvular leakage, and thrombosis.
A retrospective observational study comparing the clinical outcomes of aortic valve replacement using porcine and bovine pericardial bioprostheses, based on nationwide administrative databases in Korea between 2003 and 2018.
First results from a prospective, multicenter, single-arm registry clinical study aimed at evaluating the safety of low-dose warfarin anticoagulation combined with aspirin in patients undergoing isolated aortic valve replacement with the On-X® prosthesis (Artivion®) after 5 years of follow-up, comparing these results with the historical control group from the randomized PROACT clinical trial.
If you wish to receive our monthly newsletter, containing all the news collected on our portal, please fill in your email address and click on the “Subscribe” button.